|
1
|
Chandrasekharan NV, Dai H, Roos KL,
Evanson NK, Tomsik J, Elton TS and Simmons DL: COX-3, a
cyclooxygenase-1 variant inhibited by acetaminophen and other
analgesic/antipyretic drugs: cloning, structure, and expression.
Proc Natl Acad Sci USA. 99:13926–13931. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dennis LK, Lynch CF and Torner JC:
Epidemiologic association between prostatitis and prostate cancer.
Urology. 60:78–83. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Howe LR: Inflammation and breast cancer.
Cyclooxygenase/prostaglandin signaling and breast cancer. Breast
Cancer Res. 9:2102007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liao X, Lochhead P, Nishihara R, et al:
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
N Engl J Med. 367:1596–1606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holmes MD, Chen WY, Li L, Hertzmark E,
Spiegelman D and Hankinson SE: Aspirin intake and survival after
breast cancer. J Clin Oncol. 28:1467–1472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stratmann N, Failing K, Richter A and
Wehrend A: Mammary tumor recurrence in bitches after regional
mastectomy. Vet Surg. 37:82–86. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Doré M, Lanthier I and Sirois J:
Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol.
40:207–212. 2003.
|
|
10
|
Queiroga FL, Alves A, Pires I and Lopes C:
Expression of Cox-1 and Cox-2 in canine mammary tumours. J Comp
Pathol. 136:177–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klopfleisch R, von Euler H, Sarli G, Pinho
SS, Gartner F and Gruber AD: Molecular carcinogenesis of canine
mammary tumors: news from an old disease. Vet Pathol. 48:98–116.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saito T, Tamura D, Nakamura T, et al:
4-methylumbelliferone leads to growth arrest and apoptosis in
canine mammary tumor cells. Oncol Rep. 29:335–342. 2013.PubMed/NCBI
|
|
13
|
Saito T, Dai T and Asano R: The hyaluronan
synthesis inhibitor 4-methylumbelliferone exhibits antitumor
effects against mesenchymal-like canine mammary tumor cells. Oncol
Lett. 5:1068–1074. 2013.
|
|
14
|
Saito T, Kawana H, Azuma K, Toyoda A,
Fujita H, Kitagawa M and Harigaya K: Fragmented hyaluronan is an
autocrine chemokinetic motility factor supported by the
HAS2-HYAL2/CD44 system on the plasma membrane. Int J Oncol.
39:1311–1320. 2011.PubMed/NCBI
|
|
15
|
Zhang GS, Liu DS, Dai CW and Li RJ:
Antitumor effects of celecoxib on K562 leukemia cells are mediated
by cell-cycle arrest, caspase-3 activation, and downregulation of
Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Am J Hematol. 81:242–255. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shishodia S, Koul D and Aggarwal BB:
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced
NF-κB activation through inhibition of activation of IκBα kinase
and Akt in human non-small cell lung carcinoma: correlation with
suppression of COX-2 synthesis. J Immunol. 173:2011–2022.
2004.PubMed/NCBI
|
|
17
|
Chipuk JE and Green DR: How do BCL-2
proteins induce mitochondrial outer membrane permeabilization?
Trends Cell Biol. 18:157–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li P, Nijhawan D, Budihardjo I,
Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and
dATP-dependent formation of Apaf-1/caspase-9 complex initiates an
apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
William WN Jr, Heymach JV, Kim ES and
Lippman SM: Molecular targets for cancer chemoprevention. Nat Rev
Drug Discov. 8:213–225. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Harris RE: Cyclooxygenase-2 (COX-2)
blockade in the chemoprevention of cancers of the colon, breast,
prostate, and lung. Inflammopharmacology. 17:55–67. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dannenberg AJ and Subbaramaiah K:
Targeting cyclooxygenase-2 in human neoplasia: rationale and
promise. Cancer Cell. 4:431–436. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Doré M: Cyclooxygenase-2 expression in
animal cancers. Vet Pathol. 48:254–265. 2011.
|
|
23
|
Dias Pereira P, Lopes CC, Matos AJ, Santos
M, Gärtner F, Medeiros R and Lopes C: COX-2 expression in canine
normal and neoplastic mammary gland. J Comp Pathol. 140:247–253.
2009.PubMed/NCBI
|
|
24
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ola MS, Nawaz M and Ahsan H: Role of Bcl-2
family proteins and caspases in the regulation of apoptosis. Mol
Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Igney FH and Krammer PH: Death and
anti-death: tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tait SW and Green DR: Mitochondria and
cell death: outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu X, Yue P, Zhou Z, Khuri FR and Sun SY:
Death receptor regulation and celecoxib-induced apoptosis in human
lung cancer cells. J Natl Cancer Inst. 96:1769–1780. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jendrossek V, Handrick R and Belka C:
Celecoxib activates a novel mitochondrial apoptosis signaling
pathway. FASEB J. 17:1547–1549. 2003.PubMed/NCBI
|
|
30
|
Jendrossek V: Targeting apoptosis pathways
by Celecoxib in cancer. Cancer Lett. 332:313–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sheng H, Shao J, Morrow JD, Beauchamp RD
and DuBois RN: Modulation of apoptosis and Bcl-2 expression by
prostaglandin E2 in human colon cancer cells. Cancer
Res. 58:362–366. 1998.PubMed/NCBI
|
|
32
|
Solomon SD, McMurray JJ, Pfeffer MA, et
al: Cardiovascular risk associated with celecoxib in a clinical
trial for colorectal adenoma prevention. N Engl J Med.
352:1071–1080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fitzgerald GA: Coxibs and cardiovascular
disease. N Engl J Med. 351:1709–1711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schönthal AH, Chen TC, Hofman FM, Louie SG
and Petasis NA: Celecoxib analogs that lack COX-2 inhibitory
function: preclinical development of novel anticancer drugs. Expert
Opin Investig Drugs. 17:197–208. 2008.PubMed/NCBI
|
